Wei Wei, PhD
Assistant Professor of Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Appointments
Medical Oncology and Hematology
Primary
Additional Titles
Interim Director of Biostatistics Shared Resource, Yale Cancer Center
Contact Info
Appointments
Medical Oncology and Hematology
Primary
Additional Titles
Interim Director of Biostatistics Shared Resource, Yale Cancer Center
Contact Info
Appointments
Medical Oncology and Hematology
Primary
Additional Titles
Interim Director of Biostatistics Shared Resource, Yale Cancer Center
Contact Info
About
Copy Link
Titles
Assistant Professor of Medicine (Medical Oncology)
Interim Director of Biostatistics Shared Resource, Yale Cancer Center
Biography
Wei Wei is an Assistant Professor in the Department of Biostatistics at the Yale School of Public Health. Dr. Wei's research area focuses on development of early phase clinical trial designs, with particular interest in cancer targeted and immunotherapeutic agents.
Last Updated on October 04, 2025.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
Education & Training
- PhD
- Medical University of South Carolina, Biostatistics (2016)
Research
Copy Link
Overview
Public Health Interests
Clinical Trials; Cancer; Biomarkers
ORCID
0000-0003-1263-5620
Research at a Glance
Yale Co-Authors
Frequent collaborators of Wei Wei's published research.
Harriet Kluger, MD
David Rimm, MD, PhD
Amit Mahajan, MD
Jan Philipp Bewersdorf, MD, FACP
Nikolai Podoltsev, MD, PhD
Daniel Zelterman, PhD
Publications
2025
Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas
Cheung J, Hunt B, Wahed S, Cheng E, Connolly K, Venkatesan S, Loza J, Bansal I, Fagerberg E, Kessler E, Riffard C, Buck J, Attanasio J, Borr E, Wei W, William I, Fitzgerald B, Joshi N. Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas. Cancer Cell 2025 PMID: 41043437, DOI: 10.1016/j.ccell.2025.09.005.Peer-Reviewed Original ResearchCitationsAltmetricFruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
Dasari A, Eng C, Lonardi S, Garcia-Carbonero R, Masuishi T, Cremolini C, Ghiringhelli F, Hubbard J, Bekaii-Saab T, Jones J, Xu RH, Shen L, Xu J, Bai Y, Deng Y, Yuan Y, Wei W, Lin J, Chen L, Yang Z, Schelman WR, Qin S, Li J. Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO. Eur J Cancer 2025, 227: 115641. PMID: 40795524, DOI: 10.1016/j.ejca.2025.115641.Peer-Reviewed Original ResearchClinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer
Ajjawi I, Rios A, Wei W, Park TS, Lustberg MB. Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2025 Jul;212(2):299-308. doi: 10.1007/s10549-025-07725-3. Epub 2025 May 15. PMID: 40369346.Peer-Reviewed Original ResearchClinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer
Ajjawi I, Rios A, Wei W, Park TS, Lustberg MB. Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer. Cancers (Basel). 2025 May 6;17(9):1579. doi: 10.3390/cancers17091579. PMID: 40361505; PMCID: PMC12072055.Peer-Reviewed Original ResearchPhase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Bhatia A, Mehra R, Bauman J, Khan S, Wei W, Neumeister V, Sandoval‐Schaefer T, Alpaugh R, Lango M, Rimm D, Ridge J, Burtness B. Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head & Neck 2025, 47: 2373-2382. PMID: 40166973, DOI: 10.1002/hed.28152.Peer-Reviewed Original ResearchThis study investigates the efficacy of adding erlotinib to chemotherapy and cetuximab for head and neck cancer, showing improved response rates, highlighting potential for dual EGFR targeting in treatment.Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMelanoma brain metastasesOverall survivalBrain metastasesAnti-vascular endothelial growth factor therapyMedian intracranial progression-free survivalFour-year OS ratesIntracranial progression-free survivalResponse rateCirculating angiopoietin-2Median overall survivalTrial of pembrolizumabYears of pembrolizumabDose of bevacizumabProgression-free survivalPhase II trialGrowth factor therapyAdverse event ratesAssociated with responseOS ratesPD-1Radiation necrosisLocal therapyOn-therapyMetastatic tumorsFactor therapyStatistical considerations for evaluating treatment effect under various non-proportional hazard scenarios
Zhang X, Greene E, Blaha O, Wei W. Statistical considerations for evaluating treatment effect under various non-proportional hazard scenarios. Statistical Methods In Medical Research 2025, 34: 986-1000. PMID: 39930911, PMCID: PMC12582275, DOI: 10.1177/09622802241313297.Peer-Reviewed Original ResearchAltmetricConceptsNon-proportional hazardsType I error rateAnalysis of time-to-event outcomesTime-to-event outcomesComparison of statistical methodsGeneralized gamma modelMaxCombo testGamma modelF modelOverall treatment effectTreatment effectsReal dataSurvival probabilityGeneralizationOncology trialsPublished oncology trialsBayesian model averaging for randomized dose optimization trials in multiple indications
Wei W, Lin J. Bayesian model averaging for randomized dose optimization trials in multiple indications. Journal Of Biopharmaceutical Statistics 2025, ahead-of-print: 1-13. PMID: 39930766, PMCID: PMC12335606, DOI: 10.1080/10543406.2025.2450325.Peer-Reviewed Original ResearchAltmetricConceptsDose-response relationshipDosing recommendationsEra of targeted agentsOncology dose-finding trialsSmall cohortPhase III doseMaximum tolerated doseDose optimization strategiesCohort of patientsDose-optimization studyOff-target toxicityDose-finding trialProof-of-concept trialsDose optimizationTargeted agentsDose-findingDose levelsAntitumor activityDoseLow prevalencePatientsTrialsOncologyAgentsOptimization trials
2024
Bayesian model averaging for dose optimization in multiple indications.
Wei Wei, Jianchang Lin. Bayesian model averaging for dose optimization in multiple indications. Accepted by Journal of Biopharmaceutical StatisticsPeer-Reviewed Original ResearchAdverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors
Kwan J, Shen M, Akhlaghi N, Hu J, Mora R, Cross J, Jiang M, Mankbadi M, Wang P, Zaman S, Lee S, Im Y, Feher A, Liu Y, S. S, Tao W, Wei W, Baldassarre L. Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors. PLOS ONE 2024, 19: e0314555. PMID: 39621799, PMCID: PMC11611253, DOI: 10.1371/journal.pone.0314555.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdverse cardiovascular eventsICI therapyCardiac magnetic resonanceIncreased risk of mortalityICI initiationIncreased riskRisk of mortalityCentral nervous systemVentricular dysfunctionCancer patients treated with ICIsCardiovascular eventsLeft ventricular late gadolinium enhancementMortality benefitCardiovascular riskAbnormal left ventricular ejection fractionPatients treated with ICIsLeft ventricular ejection fractionCentral nervous system malignanciesRisk of adverse cardiovascular eventsImmune checkpoint inhibitorsRight ventricular dysfunctionGlobal longitudinal strainVentricular ejection fractionLeft ventricular dysfunctionMultimodality cardiac imaging
Academic Achievements & Community Involvement
Copy Link
Activities
activity Leukemia & Lymphoma Society
2025 - PresentPeer Review Groups and Grant Study SectionsGrant Revieweractivity Design and Implementation of Clinical Trials
11/17/2025 - 11/21/2025LectureWinn-AACR Design and Implementation of Clinical Trials WorkshopDetailsAlbuquerque, NM, United StatesSponsored by American Association for Cancer ResearchCollaborators
Teaching & Mentoring
Copy Link
Mentoring
Jinping Liang
Graduate student2025 - PresentMichelle Song
Graduate student2025 - PresentYunhe Liu
Graduate student at YSPH2022 - 2024Yunxuan Zhang
Graduate student at YSPH2022 - 2023
Willing and Available to Mentor
- Students
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Email